3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
2
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Breast Neoplasms
44
Prostatic Neoplasms
35
Lung Neoplasms
29
Multiple Myeloma
24
Neoplasms
22
Colorectal Neoplasms
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Ovarian Neoplasms
17
Neoplasm Metastasis
17
Leukemia, Lymphocytic, Chronic, B-Cell
17
Carcinoma, Renal Cell
15
Pancreatic Neoplasms
13
Small Cell Lung Carcinoma
12
Endometrial Neoplasms
12
Urinary Bladder Neoplasms
10
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Leukemia, Myeloid, Acute
10
Myasthenia Gravis
9
Lymphoma, Follicular
9
Fallopian Tube Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
8
Colonic Neoplasms
8
Recurrence
7
Burkitt Lymphoma
7
Lymphoma, Mantle-Cell
6
Esophageal Neoplasms
6
Carcinoma
6
Biliary Tract Neoplasms
6
Interventions
liposomal doxorubicin
1
Topotecan
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
30 days
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled